NY-CIRIUM
23.8.2022 14:02:54 CEST | Business Wire | Press release
Cirium, the aviation analytics firm, has announced that former Spirit Airlines CEO, Ben Baldanza and former Indigo CCO, Willy Boulter have joined the Cirium On-Time Performance (OTP) Advisory Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005442/en/
Cirium is the first and only company that has an OTP Advisory Board in the aviation industry. The Board comprises a collaborative team of external advisors who support Cirium’s OTP Program and reports global Annual and Monthly airline and airport on-time analyses.
“We are delighted to welcome Ben and Willy to the Cirium OTP Advisory Board. Together they bring nearly 80 years of aviation experience to the Board, which will be invaluable for Cirium’s airline and airport OTP Program. They will provide key focus and direction on the big-picture initiatives,” said Jeremy Bowen , CEO at Cirium.
Ben Baldanza is a transformational leader in the US airline industry. He was president and CEO for Spirit Airlines and changed that airline into an ultra-low-cost-airline carrier. Prior to Spirit he held executive roles with US Airways, Continental Airlines and TACA Airlines.
In addition to the Cirium OTP Board, Baldanza currently serves on the Board of Directors for JetBlue Airways, Six Flags Entertainment and several private companies. He also co-hosts a weekly podcast that is now in the top 1% of all podcasts by weekly listeners. Baldanza has also been twice named as one of the industry’s 25 Most Influential Leaders .
Baldanza said: “Airline and airport operational performance is increasingly important as the industry recovers from the pandemic and contends with rising challenges such as forecasting travel demand. Cirium’s OTP Program measures the carriers’ and airports’ operational efficiencies and is the standard for on-time arrival and departure benchmarking.”
Willy Boulter has 40 years’ experience in the airline industry, most recently as CCO at India’s largest airline IndiGo. Prior to IndiGo, Boulter was CCO in the Emirates-sponsored team that turned around TAAG Angola Airlines. He held executive roles at Gulf Air, Etihad Airways, low-cost carrier Sky Express, Virgin Atlantic and Cathay Pacific. Boulter also served in the British Army in the UK, Canada and Hong Kong and is a fellow of the Royal Aeronautical Society.
Boulter said: “It’s a privilege to join the Cirium OTP Advisory Board to help steer an accurate analysis of airline and airport operations. The program has multiple benefits for the industry, not least enabling improved operational performance and tracking aircraft utilization aligned to sustainability targets.”
Baldanza and Boulter join Luis Felipe de Oliveira , Director General at ACI World and Henry H. Harteveldt, President – Travel Industry Analyst at Atmosphere Research Group on the Board.
Click here to download the latest Cirium On-Time Performance Monthly Report.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005442/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom